SEC Form 4 · accession 0001009448-17-000039
Bionik Laboratories Corp. · BNKL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy A. McCarthy
Officer — Chief Commercialization Office
Period of report
Aug 3, 2017
Accepted (ET)
Aug 24, 2017 · 3:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001508381
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.21 | Aug 3, 2017 | A | 1,500,000 | A | — | Aug 3, 2024 | Common Stock | 1,500,000 | 1,500,000 | D |
| Employee Stock Option (Right to Buy)F2 | $0.21 | Aug 3, 2017 | A | 250,000 | A | — | Aug 3, 2024 | Common Stock | 250,000 | 250,000 | D |
| Employee Stock Option (Right to Buy)F3 | $0.21 | Aug 3, 2017 | A | 250,000 | A | — | Aug 3, 2024 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1Reporting person was granted a stock option which shall vest equally over a 3 year period commencing one year from the date of grant and in the two subsequent years on the anniversary of the grant date.
- F2Reporting person was granted a stock option which shall vest upon, and if and only if, the Company achieves no less than $5.0 million in sales (as provided in the Company's audited Consolidated Statements of Operations and Comprehensive (Loss) Income) for the fiscal year ending March 31, 2019.
- F3Reporting person was granted a stock option which shall vest upon, and if and only if, the Company achieves no less than $10.0 million in sales (as provided in the Company's audited Consolidated Statements of Operations and Comprehensive (Loss) Income) for the fiscal year ending March 31, 2020.